Chronic Low Dose Prostaglandin and Neonatal Heart Block

Area of Science:

• Neonatal Cardiology
• Pediatric Pharmacology
• Congenital Heart Disease

Background:

• Prostaglandin E1 (PGE1) is crucial for maintaining ductus arteriosus patency in neonates with congenital heart defects like coarctation of the aorta.
• Commonly reported side effects of long-term prostaglandin use include bone and soft tissue abnormalities.

Observation:

• A neonate with critical coarctation of the aorta experienced second and third-degree atrioventricular blocks during a prolonged Prostaglandin E1 (PGE1) infusion.
• These cardiac conduction abnormalities were observed specifically at low doses of PGE1.

Findings:

• The study identified a novel association between low-dose Prostaglandin E1 (PGE1) infusion and severe atrioventricular blocks in a neonate with critical aortic coarctation.
• Resolution of atrioventricular blocks occurred promptly upon cessation of PGE1 infusion.

Implications:

• This case highlights a potential risk of cardiac conduction disturbances with PGE1 use in neonates, even at low therapeutic doses.
• Careful cardiac monitoring is warranted during PGE1 therapy, particularly in neonates with complex congenital heart disease.
• The findings suggest a need for further investigation into the dose-dependent effects of PGE1 on cardiac electrophysiology in neonates.